Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 9/2014

01.09.2014 | Original Article

The impact of bone mineral density testing, fracture assessment, and osteoporosis education in men treated by androgen deprivation for prostate cancer: a pilot study

verfasst von: Michelle Nadler, Shabbir Alibhai, Pamela Catton, Charles Catton, Jennifer Jones

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Men receiving androgen deprivation therapy for prostate cancer have low knowledge of osteoporosis (OP) and engage in few healthy bone behaviors (HBBs). A multicomponent intervention was piloted in this population. Changes in OP knowledge, self-efficacy, health beliefs, and engagement in HBBs were evaluated.

Methods

A pre-post pilot study was performed in a convenience sample of men recruited from the Princess Margaret Cancer Centre. Men were sent personalized letters explaining their dual x-ray absorptiometry (DXA) results and fracture risk assessment with an OP-related education booklet. Participants completed questionnaires assessing OP knowledge, self-efficacy, health beliefs, and current engagement in HBBs at baseline (T1) and 3 months post-intervention (T2). Paired t tests and McNemar’s test were used to assess changes in outcomes.

Results

A total of 148 men completed the study. There was an increase in OP knowledge (9.7 ± 4.3 to 11.4 ± 3.3, p < 0.0001) and feelings of susceptibility (16.5 ± 4.3 to 17.4 ± 4.7, p = 0.015), but a decrease in total self-efficacy (86.3 ± 22.9 to 81.0 ± 27.6, p = 0.007) from baseline to post-intervention. Men made appropriate changes in their overall daily calcium intake (p ≤ 0.001), and there was uptake of vitamin D supplementation from 44 % (n = 65) to 68 % (n = 99) (p < 0.0001). Men with bone loss (osteopenia or OP) had a greater change in susceptibility (1.9 ± 4.3 vs. −0.22 ± 4.2, p = 0.005) compared to men with normal bone density.

Conclusions

Our results provide preliminary evidence that a multicomponent intervention such as the one described can lead to increased knowledge and feelings of susceptibility regarding OP and can enhance uptake of some HBBs.
Literatur
1.
D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299(3):289–295PubMed
2.
Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ et al (2008) Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26(4):585–591PubMedCrossRef
3.
Saylor PJ, Morton RA, Hancock ML, Barnette KG, Steiner MS, Smith MR (2011) Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. J Urol 186(2):482–486PubMedCentralPubMedCrossRef
4.
5.
American Cancer S. Cancer Facts & Figures 2010. Atlanta: American Cancer Society
6.
Saylor PJ, Keating NL, Smith MR (2009) Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med 24(Suppl 2):S389–S394PubMedCrossRef
7.
Alibhai SM, Gogov S, Allibhai Z (2006) Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 60(3):201–215PubMedCrossRef
8.
Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE et al (2010) Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 184(3):918–923PubMedCrossRef
9.
Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN et al (2009) NCCN task force report: bone health in cancer care. J Nat Compr Cancer Netw 7(Suppl 3):S1–S32, quiz S3-5
10.
Michaud LB (2010) Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer. Am J Health Syst Pharm 67(7 Suppl 3):S20–S30, quiz S1-3PubMedCrossRef
11.
D'Alesio V, Salvig BE, Fourakre TN (2011) Evaluation of osteoporosis risk assessment in veterans receiving androgen-deprivation therapy. Consult Pharm 26(1):43–47PubMedCrossRef
12.
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2):154–164PubMedCrossRef
13.
Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90(12):6410–6417PubMedCrossRef
14.
Israeli RS, Ryan CW, Jung LL (2008) Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol 179(2):414–423PubMedCrossRef
15.
Serpa Neto A, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FL et al (2010) A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma. BMC Urol 10:9PubMedCentralPubMedCrossRef
16.
Lattouf JB, Saad F (2010) Bone complications of androgen deprivation therapy: screening, prevention, and treatment. Curr Opin Urol 20(3):247–252PubMedCrossRef
17.
Taylor LG, Canfield SE, Du XL (2009) Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115(11):2388–2399PubMedCrossRef
18.
Fink HA, Ensrud KE, Nelson DB, Kerani RP, Schreiner PJ, Zhao Y et al (2003) Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT). Osteoporos Int 14(1):69–76PubMedCrossRef
19.
Oefelein MG, Ricchiuti V, Conrad W, Resnick MI (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168(3):1005–1007PubMedCrossRef
20.
Ali NS, Shonk C, El-Sayed MS (2009) Bone health in men: influencing factors. Am J Health Behav 33(2):213–222PubMedCrossRef
21.
Hamdy RC, Baim S, Broy SB, Lewiecki EM, Morgan SL, Tanner SB et al (2010) Algorithm for the management of osteoporosis. South Med J 103(10):1009–1015, quiz 16PubMedCrossRef
22.
Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S et al (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19(4):437–447PubMedCentralPubMedCrossRef
23.
Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182(17):1864–1873PubMedCentralPubMedCrossRef
24.
Duncan GG, Corbett T, Lukka H, Warde P, Pickles T (2006) GU radiation oncologists consensus on bone loss from androgen deprivation. Can J Urol 13(1):2962–2966PubMed
25.
Adler RA (2011) Management of osteoporosis in men on androgen deprivation therapy. Maturitas 68(2):143–147PubMedCrossRef
26.
Ito K, Elkin EB, Girotra M, Morris MJ (2010) Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 152(10):621–629PubMedCrossRef
27.
Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav JE, Stuck AE, Theiler R et al (2009) Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 339:b3692PubMedCentralPubMedCrossRef
28.
Sherrington C, Whitney JC, Lord SR, Herbert RD, Cumming RG, Close JC (2008) Effective exercise for the prevention of falls: a systematic review and meta-analysis. J Am Geriatr Soc 56(12):2234–2243PubMedCrossRef
29.
Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU (2010) Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 28(2):340–347PubMedCrossRef
30.
Alibhai SM, Yun L, Cheung AM, Paszat L (2012) Screening for osteoporosis in men receiving androgen deprivation therapy. JAMA 307(3):255–256PubMedCrossRef
31.
Al-Shamsi HO, Lau AN, Malik K, Alamri A, Ioannidis G, Corbett T et al (2012) The current practice of screening, prevention, and treatment of androgen-deprivation-therapy induced osteoporosis in patients with prostate cancer. J Oncol 2012:958596PubMedCentralPubMedCrossRef
32.
Nadler M, Alibhai S, Catton P, Catton C, To MJ, Jones JM (2013) Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer. BJU Int 118(8):1301–1309CrossRef
33.
Walker LM, Tran S, Wassersug RJ, Thomas B, Robinson JW (2012) Patients and partners lack knowledge of androgen deprivation therapy side effects. Urol Oncol
34.
Panju AH, Breunis H, Cheung AM, Leach M, Fleshner N, Warde P et al (2009) Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. BJU Int 103(6):753–757PubMedCrossRef
35.
36.
Rosenstock IM, Strecher VJ, Becker MH (1988) Social learning theory and the Health Belief Model. Health Educ Q 15(2):175–183PubMedCrossRef
37.
Harrison JA, Mullen PD, Green LW (1992) A meta-analysis of studies of the Health Belief Model with adults. Health Educ Res 7(1):107–116PubMedCrossRef
38.
Painter JE, Borba CP, Hynes M, Mays D, Glanz K (2008) The use of theory in health behavior research from 2000 to 2005: a systematic review. Ann Behav Med 35(3):358–362PubMedCrossRef
39.
40.
Laslett LL, Lynch J, Sullivan TR, McNeil JD (2011) Osteoporosis education improves osteoporosis knowledge and dietary calcium: comparison of a 4 week and a one-session education course. Int J Rheum Dis 14(3):239–247PubMedCrossRef
41.
Francis KL, Matthews BL, Van Mechelen W, Bennell KL, Osborne RH (2009) Effectiveness of a community-based osteoporosis education and self-management course: a wait list controlled trial. Osteoporos Int 20(9):1563–1570PubMedCrossRef
42.
Drieling RL, Ma J, Thiyagarajan S, Stafford RS (2011) An Internet-based osteoporotic fracture risk program: effect on knowledge, attitudes, and behaviors. J Womens Health (Larchmt) 20(12):1895–1907CrossRef
43.
Werner P (2005) Knowledge about osteoporosis: assessment, correlates and outcomes. Osteoporos Int 16(2):115–127PubMedCrossRef
44.
Babatunde OT, Himburg SP, Newman FL, Campa A, Dixon Z (2011) Theory-driven intervention improves calcium intake, osteoporosis knowledge, and self-efficacy in community-dwelling older Black adults. J Nutr Educ Behav 43(6):434–440PubMedCrossRef
45.
Aree-Ue S, Pothiban L, Belza B, Sucamvang K, Panuthai S (2006) Osteoporosis preventive behavior in Thai older adults: feasibility and acceptability. J Gerontol Nurs 32(7):23–30PubMed
46.
Marci CD, Anderson WB, Viechnicki MB, Greenspan SL (2000) Bone mineral densitometry substantially influences health-related behaviors of postmenopausal women. Calcif Tissue Int 66(2):113–118PubMedCrossRef
47.
Brask-Lindemann D, Cadarette SM, Eskildsen P, Abrahamsen B (2011) Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results. Osteoporos Int 22(5):1493–1501PubMedCrossRef
48.
Doheny MO, Sedlak CA, Estok PJ, Zeller RA (2011) Bone density, health beliefs, and osteoporosis preventing behaviors in men. Orthop Nurs 30(4):266–272PubMedCentralPubMedCrossRef
49.
Doheny MO, Sedlak CA, Hall RJ, Estok PJ (2010) Structural model for osteoporosis preventing behavior in men. Am J Men's Health 4(4):334–343CrossRef
50.
Patel A, Coates PS, Nelson JB, Trump DL, Resnick NM, Greenspan SL (2003) Does bone mineral density and knowledge influence health-related behaviors of elderly men at risk for osteoporosis? J Clin Densitom 6(4):323–330PubMedCrossRef
51.
Davison BJ, Wiens K, Cushing M (2011) Promoting calcium and vitamin D intake to reduce the risk of osteoporosis in men on androgen deprivation therapy for recurrent prostate cancer. Support Care Cancer
52.
Ancker JS, Senathirajah Y, Kukafka R, Starren JB (2006) Design features of graphs in health risk communication: a systematic review. J Am Med Inform Assoc 13(6):608–618PubMedCentralPubMedCrossRef
53.
Ancker JS, Chan C, Kukafka R (2009) Interactive graphics for expressing health risks: development and qualitative evaluation. J Health Commun 14(5):461–475PubMedCrossRef
54.
Lewiecki EM (2010) Risk communication and shared decision making in the care of patients with osteoporosis. J Clin Densitom 13(4):335–345PubMedCrossRef
55.
Lewiecki EM (2011) The role of risk communication in the care of osteoporosis. Curr Osteoporos Rep 9(3):141–148PubMedCrossRef
56.
Ailinger RL, Lasus H, Braun MA (2003) Revision of the facts on osteoporosis quiz. Nurs Res 52(3):198–201PubMedCrossRef
57.
Gaines JM, Marx KA, Narrett M, Caudill J, Landsman J, Parrish JM (2011) Validation of the male osteoporosis knowledge quiz. Am J Men's Health 5(1):78–83CrossRef
58.
Horan ML, Kim KK, Gendler P, Froman RD, Patel MD (1998) Development and evaluation of the Osteoporosis Self-Efficacy Scale. Res Nurs Health 21(5):395–403PubMedCrossRef
59.
Kim KK, Horan ML, Gendler P, Patel MK (1991) Development and evaluation of the Osteoporosis Health Belief Scale. Res Nurs Health 14(2):155–163PubMedCrossRef
60.
Magkos F, Manios Y, Babaroutsi E, Sidossis LS (2006) Development and validation of a food frequency questionnaire for assessing dietary calcium intake in the general population. Osteoporos Int 17(2):304–312PubMedCrossRef
61.
Godin G (1997) Godin leisure-time exercise questionnaire. Med Sci Sports Exerc 29(June Supplement):S36–S38
62.
Arkowitz H, Westra HA (2009) Introduction to the special series on motivational interviewing and psychotherapy. J Clin Psychol 65(11):1149–1155PubMedCrossRef
63.
Dunniway DL, Camune B, Baldwin K, Crane JK (2012) FRAX(R) counseling for bone health behavior change in women 50 years of age and older. J Am Acad Nurse Pract 24(6):382–389PubMedCrossRef
Metadaten
Titel
The impact of bone mineral density testing, fracture assessment, and osteoporosis education in men treated by androgen deprivation for prostate cancer: a pilot study
verfasst von
Michelle Nadler
Shabbir Alibhai
Pamela Catton
Charles Catton
Jennifer Jones
Publikationsdatum
01.09.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2014
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2183-6

Weitere Artikel der Ausgabe 9/2014

Supportive Care in Cancer 9/2014 Zur Ausgabe

Original Article

Finding new bearings: a qualitative study on the transition from inpatient to ambulatory care of patients with acute myeloid leukemia

Original Article

Does perceived control predict Complementary and Alternative Medicine (CAM) use among patients with lung cancer? A cross-sectional survey

Original Article

Validation and feasibility of a caloric expenditure measuring device in women with early-stage breast cancer

Letter to the editor

Response to Andrea Tendas et al.’s making quality of life assessment a dashboard for patients management

Original Article

The impact of radiotherapy on quality of life for cancer patients: a longitudinal study

Original Article

Risk of unplanned visits for colorectal cancer outpatients receiving chemotherapy: a case-crossover study

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise